Matthew Callahan, Executive Director of Botanix Pharmaceuticals (ASX:BOT), discusses the company’s strategy following the US launch of Sofdra, a topical gel for hyperhidrosis. With dermatology products reaching peak revenue within three months, analysts project revenue between $15m and $20m this financial year, rising to $100m next year. Callahan highlights the company’s direct-to-patient platform, which enhances profitability by reducing distribution costs and ensuring patient adherence through automatic refills. Botanix remains focused on scaling Sofdra’s rollout while evaluating opportunities to leverage its platform for further expansion.
27 May 2021 - Next Science Limited (ASX:NXS) Founder and Chief Technology Officer Dr Matthew Myntti talks about the problem of biofilms, Next Science's antimicrobial treatments and the company's recent FDA approval.
24 Oct 2019 - BOTTY Limited Founder & CEO, Cary Gee, talks about his Conversational Commerce solution for merchants and how it leverages existing social messaging platforms to create an integrated customer engagement, analytics, payment and delivery solution.
12 Aug 2022 - Magnis Energy Technologies Limited (ASX:MNS) Executive Chairman Frank Poullas discusses the pathway to revenues and increasing capacity as the company's battery gigafactory commences production.
07 Jun 2023 - Larvotto Resources Limited (ASX:LRV) Managing Director Ron Heeks discusses the company's projects, commenting on their rare earths, gold, copper, cobalt, lithium and PGE potential.
08 Nov 2023 - Hatch Managing Director of Australia and Asia Jan Kwak discusses key commodities, geographical opportunities, innovation, applying the circular economic model to mining, and the process of producing feasibility studies.
16 Oct 2023 - BluGlass Limited (ASX:BLG) CEO Jim Haden discusses the company's being named a hub member of the US Department of Defense's Microelectronics Commons.
21 Oct 2019 - PPK Group Limited (ASX:PPK) Executive Chairman, Robin Levinson talks about FY19 results, strategy, pickup in the company's key market, and the company's joint venture with Deakin University for Boron Nitrate Nanotubes.
30 November 2022 - James Powell, the General Manager - Investor Relations, Corporate Affairs and Sustainability of the Rural Funds Group Limited (ASX:RFF) presents on the group's FY22 financial results.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
